ArticleClinical & experimental metastasis2013
Risk factors and survival outcomes in patients with brain metastases from breast cancer.
Article in Clinical & experimental metastasis, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Brain metastases for Her2 positive breast cancer patients: a systematic review (on the behalf of Italian Association of Radiotherapy and Clinical Oncology).La Radiologia medica · 2026Pooled it
- Machine learning identifies prognosticators of intracranial metastatic disease in patients with breast or lung cancer.Communications medicine · 2026Article
- Individualized prediction of brain metastasis risk in patients with breast cancer.Journal of neuro-oncology · 2026Article
- Prevention of Brain Metastases: A New Frontier.Cancers · 2024Review
- Survival analysis of patients with brain metastases at initial breast cancer diagnosis over the last decade.Breast cancer research and treatment · 2024Article
- Survival Analysis of Male Patients with Brain Metastases at Initial Breast Cancer Diagnosis over the Last Decade.Medical sciences (Basel, Switzerland) · 2024Article
- The relationship between brain metastasis and HER2 expression status in gastric cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Article
- Advances in the Management of Central Nervous System Metastases from Breast Cancer.International journal of molecular sciences · 2022Review
- COMT rs737865 mediates chemobrain in breast cancer patients with various levels of Ki-67.American journal of cancer research · 2022Article
- Article
- Review
- Heterogeneity of Tumors in Breast Cancer: Implications and Prospects for Prognosis and Therapeutics.Scientifica · 2020Review
- Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center.BMC pharmacology & toxicology · 2019Observational
- Development and validation of a novel nomogram for predicting distant metastasis-free survival among breast cancer patients.Annals of translational medicine · 2019Article
- Activity of Eribulin Mesylate in Brain Metastasis from Breast Cancer: A Stone in a Pond?Oncology · 2018Article
- De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype.Clinical & experimental metastasis · 2017Article
- Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study.JAMA oncology · 2017Article
- Predictive and Prognostic Brain Metastases Assessment in Luminal Breast Cancer Patients: FN14 and GRP94 from Diagnosis to Prophylaxis.Frontiers in oncology · 2017Article
- Methods and results of local treatment of brain metastases in patients with breast cancer.Contemporary oncology (Poznan, Poland) · 2016Review
- Prognostic factors and survival of patients with brain metastasis from breast cancer who underwent craniotomy.Cancer medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Development of central nervous system (CNS) metastases in breast cancer (BC) is associated with poor prognosis. The incidence of CNS metastases in metastatic BC is reported to be about 10-16 %, but different subtypes of BC are associated with different risk of developing CNS metastases. We retrospectively analysed the risk of CNS metastases and the outcome in a cohort of 473 patients with metastatic BC. CNS metastases were diagnosed in 15.6 % of patients and median survival from diagnosis of CNS metastases was 7.53 (25th-75th 2.8-18.9) months. The risk of developing CNS metastases was higher in patients with grade 3, hormone receptor negative, HER2-positive, high Ki-67 BC. When compared to luminal A subtype, only HER2-positive BC was associated with increased risk of CNS metastases. Survival from diagnosis of CNS metastases was longer in patients with HER2-positive BC, while it was shorter in patients that did not receive any locoregional treatment, or with extra-CNS disease, or with more than 3 CNS lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.